Adimmune Corporation (4142) AI Stock Analysis

Adimmune Corporation

(TWSE:4142)

Select Model

Rating:38Underperform

Price Target:TWD 15.50▼(-6.63% Downside)

Action:initiatedcoverage

Date:11/10/26

Poor financial performance with revenue declines, sustained losses and cash flow instability is the primary driver of the low score, followed by weak technical momentum and unattractive valuation.

Positive Factors

Biologics and Vaccine PlatformA focused vaccine and biologics platform gives Adimmune exposure to healthcare and public-health demand while building specialized R&D and production capabilities. These activities can support recurring commercial opportunities and provide a foundation for longer-term product development beyond any single reporting period.

Negative Factors

Sustained Losses and Margin CompressionPersistent operating and net losses weaken the company’s ability to self-fund research, production, and growth initiatives. The sharp decline in gross margin also suggests that higher revenue has not translated into durable profitability, leaving earnings recovery dependent on substantial margin improvement.

Adimmune Corporation (4142) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 7.08B
Dividend Yield: ―
Average Volume (3M): 994.87K
Price to Earnings (P/E): -48.7
Beta (1Y): 0.47
Revenue Growth: 34.06%
EPS Growth: ―
Country: TW
Employees: 564
Sector: General
Sector Strength: 55
Industry: Biotechnology

Adimmune Corporation Business Overview & Revenue Model

Company Description

Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influen...

Adimmune Corporation Financial Statement Overview

Summary

Revenue peaked in 2022 then declined with gross margins at 21%, persistent net losses, volatile negative operating and free cash flows, plus rising debt-to-equity at 0.57 signal elevated financial pressure.

Income Statement

28Negative

Balance Sheet

42Neutral

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.37B	1.40B	1.56B	1.79B	2.25B	1.64B
Gross Profit	306.32M	288.49M	448.06M	410.94M	891.08M	464.14M
EBITDA	-40.87M	-144.69M	-84.30M	-512.43M	438.12M	254.89M
Net Income	-233.50M	-239.89M	-242.75M	-639.89M	290.98M	43.07M
Balance Sheet
Total Assets	8.11B	8.19B	8.48B	9.48B	9.15B	8.01B
Cash, Cash Equivalents and Short-Term Investments	1.82B	2.24B	2.47B	2.49B	2.97B	2.89B
Total Debt	3.03B	2.83B	2.60B	3.14B	2.26B	1.32B
Total Liabilities	3.41B	3.14B	2.92B	3.71B	2.60B	1.58B
Stockholders Equity	4.62B	4.94B	5.23B	5.47B	6.12B	6.15B
Cash Flow
Free Cash Flow	-264.41M	-242.18M	513.26M	-1.11B	-711.59M	-1.33B
Operating Cash Flow	-64.25M	-5.45M	668.48M	-892.35M	-291.96M	-480.52M
Investing Cash Flow	-171.79M	-198.98M	-310.90M	-366.56M	-322.07M	-728.84M
Financing Cash Flow	147.63M	56.19M	-478.80M	859.30M	823.19M	-222.89M

Adimmune Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4142 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4169	54Neutral	TWD 7.93B	-291.25	―	0.27%	―	―
TW:4174	48Neutral	TWD 7.23B	-2.37	―	―	-2.20%	29.08%
TW:4128	44Neutral	TWD 7.85B	24.61	―	―	4.85%	―
TW:6541	43Neutral	TWD 7.47B	-5.03	-26.61%	―	207.37%	4.17%
TW:4142	38Underperform	TWD 7.22B	-48.68	―	―	34.06%	―

* General Sector Average

Performance Comparison

TW:4142 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4142	Adimmune Corporation	16.60	-3.00	-15.31%
TW:6541	Tanvex Biopharma	28.15	-27.55	-49.46%
TW:4128	Microbio Co., Ltd.	13.45	-7.35	-35.34%
TW:4169	TCM Biotech International Corp.	116.50	-64.77	-35.73%
TW:4174	OBI Pharma, Inc.	60.50	11.70	23.98%
TW:7876	Obigen Pharma, Inc.	66.20	29.51	80.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Adimmune Corporation AI Stock Analysis